ABSTRACT
Although most insulin-like growth factor 1 (IGF-I) in the circulation is generated by the liver, the hormone is also produced locally by the vasculature, suggesting its potential importance in regulation of regional blood flow. Accordingly, we studied the effects of in viuo exposure to IGF-l(5.1 nmol, iv) as well as in vitro incubation (100 nM) on endothelium-intact rat tail artery contractile responses to KC1 and norepinephrine (NE). I NSULIN-LIKE growth factor I (IGF-I) has long been associated with growth and differentiation.
However, it is now generally accepted that it also exerts many metabolic effects similar to those of insulin, including glucose uptake, glycogen synthesis, and amino acid transport (1,2). There is preliminary evidence that, like insulin, IGF-I may contribute to the regulation of vascular tone (3-6). Several studies suggest that the vascular actions of insulin vary in different vascular beds: inhibition of contraction in femoral, aortic, and tail vasculature and enhancement of it in mesenteric arteries (7-9). Regional differences in vascular responses to IGF-I may exist as well (9). Infusions of recombinant human IGF-I into both humans and rats increase renal blood flow and decrease vascular resistance in that organ (10,ll). Unlike insulin, however, IGF-I is produced locally (12) and, therefore, may potentially be a more important regulator of regional blood flow.
The endothelium-derived relaxing factor, nitric oxide (NO), is believed to be an important mediator of both insulinand IGF-I-induced vascular relaxation (13) (14) (15) (16) (17) , but other mechanisms have also been implicated (18) (19) (20) . Systemic infusions of either insulin or IGF-I can elicit vasodilation through metabolic processes (21) and activate a number of counterregulatory mechanisms (22, 23) , making interpretation difficult. 111 z~itm, isolated vessels require preexposure to insulin or IGF-I (5, 9, 24), suggesting that complex mechanisms are involved in the vascular actions of these hormones. Accordingly, we used a dual ex zlizlo/in zlitro approach to examine the role of NO in mediating the effects of IGF-I on the rat tail artery, a prototypical resistance vessel. 
Materials and Methods

Animals
Vascular contractility
After death, the rat tail artery was dissected free and placed in ice-
EDTA, and 5.6 mol/L glucose. Three-millimeter rings were suspended from isometric force transducers (Gould Instruments, Cleveland, OH) in muscle baths containing the same buffer at about 37 C and aerated with 95% 02-5% CO, to maintain pH. All rings were stretched to 1 g of tension and allowed to stabilize for 30 min before the addition of agonists (24). In experiments in which rings were preincubated irk r,itro, IGF-I (10 and 100 nM) was added 30, 60, or 90 min before agonist addition [l.O-120 mM KCI or 1 nM to 10 FM norepinephrine (NE)]. To evaluate the role of nitric oxide, L-nitroarginine methyl ester (L-NAME; 100 FM) was added 5 min before IGF-I. Acetyl choline (10 FM) was used to test endothelial integrity. All chemicals and drugs were purchased from Sigma.
Vascular NO production
Rat tail arteries did not provide enough tissue mass for the following studies, so aortae were used instead. The vessels were removed from Sprague-Dawley rats and carefully cleaned of fat to maintain the endothelium.
Seven vessels were then incubated in an organ chamber in the buffer used for contractility under constant aeration with 95% 0,.5% CO1 and with and without IGF-1 (100 mM). After 90 min, aliquots of the buffer were assayed for nitrites/nitrates as an index of NO production using the Griess reagent (Cayman, Ann Arbor, Ml). Values in the text are given as the average 2 SEM, and P < 5% is considered significant.
Results
In vivo
Systemic infusion of 5.1 nmol IGF-I as a bolus significantly, but transiently, decreased blood pressure in male Wistar rats. As shown in Fig. 1 , the effect was maximal at 15 min (14.1 +-3.0%; P < O.OOl), but blood pressure was normalized by 60 min. Plasma glucose was significantly reduced when measured 30 min after ICF-I injection (54.9 + 9.3 ~1s. 98.2 ? 7.3 mg/dl at baseline; P < 0.01, by paired t analysis in 11 ani- mals). Blood pressure and heart rate had returned to normal at the time of death for EX zh contractility studies.
Ex viuo contractility Although in zCz)o blood pressure had stabilized to control levels when tail arteries were removed for study, irl 7Cfro responses to both NE and KC1 were significantly attenuated (Fig. 2) . This was mostly the result of a decrease in contractility in response to both agents (final tension, 725 + 106 ~1s. 1681 ? 218 mg in controls for KCl; 951 + 134 ~1s. 1935 2 311 mg in control rings for NE), as the ED,,, values, although higher (5.5 ? 4.2 us. 1.5 + 0.5 pM for NE; 19.5 + 9.6 ~1s. 10.3 i-2.3 mM for KCl) were not significantly different.
In vitro response to IGF-I
The results of in zlitro preincubation of tail artery rings with 100 nM IGF-I for 90 min essentially paralleled those found after in viz10 exposure (Fig. 3) ] for NE, 10.9 2 3.1 Z'S, 5.2 5 1.8 PM in controls; for KCI, 10.2 i-1.6 21s. 8.4 +-0.8 mM in control rings). Preincubation with 10 mM IGF-I for the same time period also tended to decrease contractility, but the effect was not significant (19% for NE and 26% for KC1 compared to controls), but exposure for shorter time periods (60 and 30 min) had no effect (data not shown). These results coupled with those of the ex ho experiments indicate that IGF-I has a direct impact on the vasculature that persists after ill zlizlo compensatory mechanisms have returned blood pressure to normal. The fact that, at least in zlifro, long (90-min) exposure times are required suggests that relatively complex mechanisms with both immediate and delayed effects may be required. 
FIG. 2. In vitro contractility
in rat tail artery rings 90 min after an iv bolus of IGF-I (5.1 nmol; as described in Materials and Methods). Maximal tension achieved was significantly lower in response to both KC1 (toppanel) and NE (bottompanel; n = 5 paired experiments each). P = 0.0002 and 0.0001, respectively, by two-way ANOVA.
t-232 W. 920 2 270 mg in control tail artery segments with an EDS,, of 4.1 k 3.4 us. 5.3 k 4.5 PM for NE in controls). Irr vitro, preincubation with L-NAME (100 PM) for 5 min before the addition of IGF-I (100 nM for 90 min) completely reversed the effect of IGF-I, enhancing maximal contractility to NE by 25% and to KC1 by 26% over those in IGF-I-treated rings (Fig.  4) . The maximal tension achieved in response to NE in the original experiments was 1981 +-77 mg in control rings and 1556 t 180 in IGF-I-treated rings; with L-NAME, tension was 1864 t 191 compared to 1496 2 188 mg in rings exposed to IGF-I only, indicating that a complete reversal of the IGF-I effect was achieved with prior exposure to L-NAME.
Again, no changes in EDs,, could be detected. Vascular 
NO generation
As shown in Fig. 5 . 4. Coincubation with L-NAME (100 FM) and IGF-I (100 nM) for 90 min reversed the IGF-I-induced inhibition (n = 9 paired artery rings,. P = 0.0007 for KCI and 0.0128 for NE, as calculated by two-way ANOVA.
Discussion
Our results indicate that IGF-I attenuates both receptormediated and voltage-induced vascular tone predominantly through direct actions on the vessel wall. We chose the rat tail artery, a highly innervated and reactive vessel, rather than the aorta for the contractility studies. Our data demonstrate that IGF-I reduces contractility in the tail artery, much as has been reported in the aorta (9) and renal artery (10, ll), but unlike that in the mesenteric artery (9). This similarity in aortic and tail artery responses to IGF-I led us to use aorta for the NO release experiments; rat tail artery rings did not provide enough material for determination of IGF-I-induced NO production.
IGF-I appears to function like insulin in human skeletal muscle blood vessels (6, 14-17). That these two hormones have comparable effects in a reactive vessel such as the rat tail artery as well as in other vascular beds is not surprising because they share similar receptors and mechanisms of action (26, 27) .
Local mechanisms by which IGF-I may decrease vascular reactivity include activation of Na',K'-adenosine triphosphatase (Na',K'-ATPase), changes in intracellular Ca' *, interactions with N-and /3-adrenergic receptors, and release of an endothelium-dependent relaxing factor, among others (28). Although IGF-I has been shown to enhance aortic Na ',K'-ATPase activity (29), a possible mechanism for its vascular effects, most reports are limited to the actions of insulin on the vessel wall. Previous studies in our laboratory and those of others have demonstrated a direct effect of insulin on VSMC (4, 5, 30, 31). In particular, insulin can inhibit agonist-and voltage-induced VSMC intracellular calcium [Ca*'], transients, thus leading to decreased vascular contraction (4,30,31). Another possible mechanism by which insulin may attenuate [Ca"], is by selective antagonism of a,-receptors, as has been reported by Lembo ef nl. (19) . Alternately, insulin has been shown to both decrease /3-adrenergic receptor binding (32) and down-regulate &-receptor activity via phosphorylation (33) . More directly, norepinephrine release into mesenteric perifusates is lowered in the presence of insulin (34) via a presynaptic inhibitory mechanism. Any or all of these actions could be invoked for IGF-I, but most do not adequately account for the lag time required in the isolated vessel ill citro or for the fact that contractile responses to both NE and KCI are impaired.
Indeed, the significant decrease in plasma glucose seen after IGF-I infusion indicates that a number of counterregulatory responses, some adrenergic, are called into play to restore glucose homeostasis and normalize blood pressure. However, the 17s ZJ~PO reduction in contractility persisted for at least 2 h after blood pressure had returned to baseline values in the intact animal. These results suggest that a persistent modification of the intracellular milieu and/or the contractile apparatus itself has been initiated by IGF-I, alone or through the release of a mediator.
That much of the IGF-I attenuation of vascular contractility can be reversed by L-NAME supports data from other laboratories indicating that both insulin and IGF-I mediate this action through the release of NO (14, 15, 21) . Both the constitutive, Ca' ' /calmodulin-dependent, NO synthase (cNOS) and the inducible, Ca* ' /calmodulin-independent, form of the enzyme (INOS), are found in the vessel wall (35) . cNOS may be activated by serine phosphorylation, followed by its translocation from the membrane to the cytosol (36) . This is an unlikely mode of control for IGF-I unless an intermediate kinase can be implicated. In addition, IGF-I can stimulate NO release from endothelial cells without increasing [Ca"], (13) , suggesting that control of the enzyme is at least multifactorial. iNOS, on the other hand, is believed to be totally transcriptionally regulated, generally by inflammatory cytokines (37) . This process is inhibited by tyrosine kinase inhibitors, such as genistein and tyrphostin (38) , making this enzyme amenable to control by IGF-I, whose receptor itself is a tyrosine kinase. In one report, concomitant exposure of vascular smooth muscle cells to cytokines and IGF-I reverses the cytokine induction of iNOS, but only one time point was examined (39) . The NO generated by either enzyme may relax muscular contraction via activation of guanylate cyclase. This, in turn, activates the sarcoplasmic reticulum Ca' ' -ATPase and sequestration of Ca' ' (40) . NO may also act in a cGMP-dependent manner to hyperpolarize the cell via an increase in the opening probability of the Ca' ' -sensitive K' channel (41) . Both mechanisms may account for part of the immediate relaxation seen after agonist-induced cNOS activation, but they may also contribute to the profound and long lasting hypotension that occurs after cytokine stimulation of iNOS. The endothelium possesses IGF-I receptors (42) and endothelial cells (13) , and intact vessels release NO in response to IGF-I, suggesting that both paracrine and autocrine effects of IGF-I may be mediated in part through NO production. Nevertheless, in our hands, IGF-I added directly to precontracted, endothelium-intact rings generates only a minor and transient relaxation (data not shown), and long preincubation times are required to observe substantial vasorelaxation, similar to earlier observations for insulin (9,24). This delayed relaxing effect of IGF-I differs from the irl D~ZJU situation, where relaxation is immediate, as would be expected from endothelial NO release. Vessels irl zlifm are not exposed to tonic NO generated by shear stress and are more tonically contracted than those irl vizm. However, unlike IGF-I, acetylcholine produces an immediate and profound relaxation when added to our vessel preparations. Thus, the possibility exists that not only the cNOS found in endothelial cells, but also the inducible synthase of both endothelial and vascular smooth muscle cells could be activated by IGF-I, which is constitutively produced by VSMC (12, 43, 44) . Our new observation that IGF stimulates a vascular increase in NO after 90 min is consistent with such a possibility. Ignarro et al. (45) have shown that NO is continuously released by both endothelial and vascular smooth muscle cells in the pulmonary circulation and that the release may be regulated by several different mechanisms.
In addition, Marczin et nl. (46) reported that inhibition of tyrosine kinase activity (an early postreceptor event in IGF-I and insulin action) suppresses NO production by VSMC. The fact that dexamethasone (an inhibitor of iNOS induction) suppresses insulin-mediated vasodilation (16) suggests that iNOS stimulation is a possible mechanism for the delayed attenuation of contractility seen with both insulin and IGF-I. Our results do not allow us to discern whether the production of NO is via stimulation of cNOS or iNOS in the endothelium, the VSMC, or both, although the time course required for IGF-I to exert its vasodilatory properties is consistent with stimulation of both. Alternately, either IGF-I and/or endothelial cell-induced NO may initiate transcription of a protein(s) involved in the regulation of vascular contraction (47) . Again, we cannot discriminate between those two possibilities. However, we can conclude that whatever the mechanism, it must be common to both receptor-and nonreceptor-mediated signaling events, because NE-and KCl-induced contractions were similarly attenuated. As such, it may be similar to the direct effect postulated by Hollenberg for epidermal growth factor, another hormone acting via a tyrosine kinase, which produced the same reduced response to both agonists (48) .
In conclusion, the results of this investigation demonstrate that IGF-I has a direct impact on the vasculature and attenuates contractility in the rat tail artery, an effect related to NO production.
As IGF-I is not only secreted by VSMC, but also stimulates vascular NO production, this hormone may play a significant paracrine/autocrine role in the regulation of local blood flow. However, the relatively long lag time required for the actions of IGF-I on the vasculature suggests that relatively complex mechanisms are involved.
